Working... Menu
Trial record 16 of 73 for:    "Paroxysmal Nocturnal Hemoglobinuria"

Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01412047
Recruitment Status : Completed
First Posted : August 8, 2011
Last Update Posted : October 18, 2017
Information provided by (Responsible Party):
Alexion Pharmaceuticals

Brief Summary:
How does long term treatment with Soliris affect HAHA in PNH patients?

Condition or disease
Paroxysmal Nocturnal Hemoglobinuria PNH

Detailed Description:
To determine the long term effect of Soliris (eculizumab) treatment on the presence of human anti-human antibodies (HAHA) in Paroxysmal Nocturnal Hemoglobinuria (PNH) patients.

Layout table for study information
Study Type : Observational
Actual Enrollment : 75 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: A Post Marketing, Multi-Center, Trial to Measure Human Anti-Human Antibodies (HAHA) to Soliris (Eculizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria
Study Start Date : March 2012
Actual Primary Completion Date : June 2013
Actual Study Completion Date : June 30, 2013

Primary Outcome Measures :
  1. To summarize the proportion of patients with neutralizing HAHA antibodies. [ Time Frame: Six (6) months ]

Secondary Outcome Measures :
  1. To summarize the proportion of patients with non-neutralizing HAHA antibodies. [ Time Frame: Six (6) months ]
  2. To summarize the proportion of patients with increased hemolysis in setting of neutralizing HAHA antibodies. [ Time Frame: Six (6) months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with PNH previously enrolled in study E05-001, who have a eculizumab naive serum sample available for comparison, and who are currently receiving treatment with commerical Soliris.

Inclusion Criteria:

  • PNH patients who previously participated in study E05-001;
  • Patients who have an eculizumab naive serum sample for comparison;
  • Patients who currently used commerical Soliris;
  • Patients who are willing and able to gie written informed consent.

Exclusion Criteria:

  • There are no exclusion criteria for this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01412047

Layout table for location information
United States, Colorado
University Park Hematology Oncology
Englewood, Colorado, United States, 80113
United States, Florida
Cleveland Clinic Florida
Weston, Florida, United States, 33331
United States, Maine
Maine Cancer Center of Medicine
Scarborough, Maine, United States, 04074
Melbourne, Australia
Brussels, Belgium
Paris, France
Universitatsklinikum Essen
Essen, Germany
Institut fur Klinische Transfusionmedizin und Immungenetick
Ulm, Germany
Dublin, Ireland
Azienda Ospediliera Universitatia Careggi
Firenze, Italy
Universita degli Studi di Napoli
Napoli, Italy
Nijmegen, Netherlands
Basel, Switzerland
United Kingdom
London, United Kingdom
Sponsors and Collaborators
Alexion Pharmaceuticals
Layout table for investigator information
Study Director: Camille Bedrosian, MD Alexion Pharmaceuticals

Layout table for additonal information
Responsible Party: Alexion Pharmaceuticals Identifier: NCT01412047     History of Changes
Other Study ID Numbers: M07-003
First Posted: August 8, 2011    Key Record Dates
Last Update Posted: October 18, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Alexion Pharmaceuticals:
Paroxysmal Nocturnal Hemoglobinuria
Human Anti-Human Antibody

Additional relevant MeSH terms:
Layout table for MeSH terms
Hemoglobinuria, Paroxysmal
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms
Anemia, Hemolytic
Hematologic Diseases
Myelodysplastic Syndromes
Bone Marrow Diseases
Immunologic Factors
Physiological Effects of Drugs